| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Injuries, Traumatic | 63 | 2026 | 317 | 11.720 |
Why?
|
| Brain Injuries | 78 | 2026 | 709 | 11.670 |
Why?
|
| Brain Concussion | 22 | 2025 | 244 | 3.910 |
Why?
|
| Cerebrovascular Circulation | 23 | 2017 | 485 | 3.530 |
Why?
|
| Intracranial Hypertension | 20 | 2025 | 137 | 3.150 |
Why?
|
| Intracranial Pressure | 19 | 2025 | 216 | 2.890 |
Why?
|
| Erythropoietin | 10 | 2019 | 104 | 2.730 |
Why?
|
| Glasgow Outcome Scale | 12 | 2025 | 50 | 2.620 |
Why?
|
| Glasgow Coma Scale | 30 | 2026 | 203 | 1.850 |
Why?
|
| Monitoring, Physiologic | 12 | 2023 | 370 | 1.710 |
Why?
|
| Biomarkers | 28 | 2026 | 3395 | 1.650 |
Why?
|
| Critical Care | 12 | 2026 | 681 | 1.440 |
Why?
|
| Recovery of Function | 11 | 2024 | 443 | 1.390 |
Why?
|
| Brain | 21 | 2025 | 3209 | 1.340 |
Why?
|
| Erythrocyte Transfusion | 4 | 2015 | 141 | 1.290 |
Why?
|
| Adult | 88 | 2026 | 31230 | 1.120 |
Why?
|
| Oxygen | 9 | 2020 | 550 | 1.100 |
Why?
|
| Hemoglobins | 4 | 2019 | 287 | 1.020 |
Why?
|
| Cerebral Cortex | 10 | 2016 | 457 | 0.970 |
Why?
|
| Glial Fibrillary Acidic Protein | 8 | 2025 | 101 | 0.970 |
Why?
|
| Intensive Care Units | 6 | 2026 | 518 | 0.960 |
Why?
|
| Neuroprotective Agents | 5 | 2012 | 159 | 0.960 |
Why?
|
| Humans | 144 | 2026 | 130599 | 0.950 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2022 | 249 | 0.920 |
Why?
|
| Middle Aged | 67 | 2026 | 28459 | 0.920 |
Why?
|
| Arginine | 7 | 2018 | 334 | 0.900 |
Why?
|
| Post-Concussion Syndrome | 3 | 2021 | 50 | 0.900 |
Why?
|
| Microdialysis | 7 | 2026 | 59 | 0.880 |
Why?
|
| Nitric Oxide | 8 | 2018 | 467 | 0.870 |
Why?
|
| Hypothermia, Induced | 2 | 2016 | 175 | 0.860 |
Why?
|
| Prospective Studies | 36 | 2025 | 6489 | 0.860 |
Why?
|
| Trauma Severity Indices | 5 | 2021 | 87 | 0.850 |
Why?
|
| Disability Evaluation | 4 | 2025 | 191 | 0.820 |
Why?
|
| Male | 97 | 2026 | 64580 | 0.820 |
Why?
|
| Young Adult | 37 | 2025 | 10011 | 0.810 |
Why?
|
| Longitudinal Studies | 9 | 2025 | 1498 | 0.740 |
Why?
|
| Prognosis | 19 | 2026 | 4927 | 0.740 |
Why?
|
| Cytokines | 3 | 2020 | 1339 | 0.740 |
Why?
|
| Injury Severity Score | 12 | 2024 | 235 | 0.730 |
Why?
|
| Interleukin-10 | 2 | 2020 | 185 | 0.710 |
Why?
|
| Shock, Hemorrhagic | 2 | 2012 | 51 | 0.690 |
Why?
|
| Female | 81 | 2026 | 70540 | 0.690 |
Why?
|
| Anemia | 3 | 2014 | 355 | 0.670 |
Why?
|
| Rats | 21 | 2023 | 3407 | 0.650 |
Why?
|
| Hemodynamics | 3 | 2015 | 812 | 0.630 |
Why?
|
| Interleukin-2 | 1 | 2020 | 236 | 0.620 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 3 | 2020 | 10 | 0.610 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2026 | 2103 | 0.600 |
Why?
|
| White Matter | 4 | 2025 | 222 | 0.600 |
Why?
|
| Disease Models, Animal | 12 | 2018 | 4647 | 0.590 |
Why?
|
| Severity of Illness Index | 7 | 2021 | 3060 | 0.580 |
Why?
|
| Rats, Long-Evans | 10 | 2019 | 96 | 0.570 |
Why?
|
| Blood Flow Velocity | 7 | 2010 | 424 | 0.570 |
Why?
|
| Brain Ischemia | 4 | 2004 | 262 | 0.570 |
Why?
|
| Craniocerebral Trauma | 3 | 2014 | 142 | 0.560 |
Why?
|
| Brain Injuries, Diffuse | 1 | 2017 | 1 | 0.550 |
Why?
|
| Multiple Organ Failure | 1 | 2019 | 144 | 0.530 |
Why?
|
| Animals | 44 | 2023 | 33829 | 0.520 |
Why?
|
| Markov Chains | 1 | 2017 | 99 | 0.510 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 747 | 0.510 |
Why?
|
| Hematoma, Subdural, Acute | 3 | 2025 | 12 | 0.500 |
Why?
|
| Models, Theoretical | 1 | 2019 | 363 | 0.500 |
Why?
|
| Arginase | 2 | 2018 | 35 | 0.450 |
Why?
|
| Cohort Studies | 15 | 2025 | 5087 | 0.450 |
Why?
|
| Cognitive Dysfunction | 3 | 2025 | 338 | 0.450 |
Why?
|
| Homeostasis | 5 | 2008 | 712 | 0.450 |
Why?
|
| Oligopeptides | 2 | 2012 | 106 | 0.450 |
Why?
|
| Head Injuries, Closed | 4 | 2012 | 45 | 0.440 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2015 | 41 | 0.440 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2014 | 15 | 0.440 |
Why?
|
| Endocrine System Diseases | 1 | 2015 | 43 | 0.430 |
Why?
|
| Pulmonary Edema | 1 | 2015 | 56 | 0.430 |
Why?
|
| Neurofilament Proteins | 2 | 2024 | 38 | 0.420 |
Why?
|
| Adolescent | 26 | 2025 | 20814 | 0.420 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2023 | 677 | 0.420 |
Why?
|
| Logistic Models | 3 | 2017 | 1823 | 0.410 |
Why?
|
| Aged | 29 | 2025 | 20939 | 0.410 |
Why?
|
| Nitric Oxide Synthase Type III | 3 | 2018 | 186 | 0.400 |
Why?
|
| Behavior, Animal | 2 | 2017 | 491 | 0.400 |
Why?
|
| Time Factors | 17 | 2024 | 6237 | 0.400 |
Why?
|
| Models, Cardiovascular | 2 | 2005 | 166 | 0.390 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2005 | 173 | 0.380 |
Why?
|
| Neurophysiological Monitoring | 4 | 2016 | 37 | 0.370 |
Why?
|
| Antioxidants | 3 | 2023 | 334 | 0.370 |
Why?
|
| Models, Statistical | 1 | 2015 | 485 | 0.370 |
Why?
|
| Blood Transfusion | 4 | 2019 | 291 | 0.360 |
Why?
|
| Blood Pressure | 5 | 2005 | 1342 | 0.350 |
Why?
|
| Reaction Time | 1 | 2012 | 156 | 0.340 |
Why?
|
| Alcoholic Intoxication | 1 | 2010 | 13 | 0.330 |
Why?
|
| Consciousness | 1 | 2010 | 56 | 0.320 |
Why?
|
| Head Injuries, Penetrating | 2 | 2020 | 8 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 1247 | 0.310 |
Why?
|
| Treatment Outcome | 17 | 2026 | 12901 | 0.310 |
Why?
|
| Length of Stay | 1 | 2015 | 1397 | 0.300 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2010 | 156 | 0.300 |
Why?
|
| Oxygen Consumption | 2 | 2008 | 301 | 0.300 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 167 | 0.300 |
Why?
|
| Critical Illness | 4 | 2017 | 615 | 0.300 |
Why?
|
| Nitric Oxide Synthase | 3 | 2004 | 167 | 0.290 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 6782 | 0.290 |
Why?
|
| Trauma Centers | 8 | 2024 | 209 | 0.280 |
Why?
|
| Ubiquitin Thiolesterase | 4 | 2025 | 64 | 0.270 |
Why?
|
| Neurosurgical Procedures | 2 | 2026 | 316 | 0.270 |
Why?
|
| Neurosciences | 1 | 2008 | 48 | 0.270 |
Why?
|
| Decompressive Craniectomy | 2 | 2017 | 11 | 0.270 |
Why?
|
| Brain Chemistry | 2 | 2004 | 111 | 0.260 |
Why?
|
| Consensus | 3 | 2026 | 528 | 0.260 |
Why?
|
| Craniotomy | 2 | 2025 | 103 | 0.260 |
Why?
|
| Resilience, Psychological | 2 | 2022 | 78 | 0.260 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2008 | 90 | 0.260 |
Why?
|
| Third-Party Consent | 1 | 2007 | 26 | 0.250 |
Why?
|
| Human Experimentation | 1 | 2007 | 33 | 0.250 |
Why?
|
| Cerebral Arteries | 2 | 2003 | 80 | 0.240 |
Why?
|
| Hyperoxia | 1 | 2008 | 135 | 0.230 |
Why?
|
| Ventriculostomy | 1 | 2006 | 46 | 0.230 |
Why?
|
| Nonlinear Dynamics | 1 | 2005 | 57 | 0.230 |
Why?
|
| Emergency Medical Services | 2 | 2007 | 420 | 0.230 |
Why?
|
| Conservative Treatment | 1 | 2025 | 43 | 0.230 |
Why?
|
| Hyperthermia, Induced | 1 | 2005 | 56 | 0.230 |
Why?
|
| Neuropsychological Tests | 4 | 2024 | 961 | 0.220 |
Why?
|
| Cyclic GMP | 1 | 2005 | 89 | 0.220 |
Why?
|
| Sensitivity and Specificity | 6 | 2015 | 2126 | 0.220 |
Why?
|
| Hippocampus | 5 | 2020 | 805 | 0.220 |
Why?
|
| Subarachnoid Hemorrhage, Traumatic | 1 | 2024 | 1 | 0.210 |
Why?
|
| Deoxyguanosine | 1 | 2004 | 12 | 0.210 |
Why?
|
| Radiography | 5 | 2015 | 739 | 0.210 |
Why?
|
| Neurons | 8 | 2018 | 1988 | 0.210 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 5226 | 0.210 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 1408 | 0.210 |
Why?
|
| Autoimmunity | 1 | 2025 | 174 | 0.210 |
Why?
|
| Receptors, Odorant | 1 | 2024 | 36 | 0.210 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2024 | 26 | 0.210 |
Why?
|
| Mental Disorders | 1 | 2012 | 894 | 0.210 |
Why?
|
| Retrospective Studies | 12 | 2025 | 17654 | 0.200 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2023 | 5 | 0.200 |
Why?
|
| Oleic Acids | 1 | 2023 | 9 | 0.200 |
Why?
|
| Chlorambucil | 1 | 2023 | 5 | 0.200 |
Why?
|
| Family | 1 | 2007 | 586 | 0.200 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 228 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2025 | 226 | 0.200 |
Why?
|
| Reference Values | 4 | 2015 | 679 | 0.200 |
Why?
|
| Hemostasis | 1 | 2003 | 76 | 0.200 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 132 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2025 | 3864 | 0.200 |
Why?
|
| Mice | 17 | 2023 | 18174 | 0.190 |
Why?
|
| Muscle Contraction | 1 | 2003 | 148 | 0.190 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2003 | 148 | 0.190 |
Why?
|
| Cerebral Infarction | 1 | 2003 | 46 | 0.190 |
Why?
|
| Pain | 1 | 2025 | 431 | 0.190 |
Why?
|
| Extracellular Vesicles | 1 | 2024 | 66 | 0.190 |
Why?
|
| Predictive Value of Tests | 7 | 2026 | 2307 | 0.190 |
Why?
|
| Computer Simulation | 3 | 2017 | 679 | 0.190 |
Why?
|
| Emergency Service, Hospital | 4 | 2026 | 1211 | 0.190 |
Why?
|
| Free Radical Scavengers | 1 | 2003 | 56 | 0.190 |
Why?
|
| Carbon | 2 | 2023 | 101 | 0.190 |
Why?
|
| Calpain | 4 | 2022 | 43 | 0.180 |
Why?
|
| Xenon | 2 | 2017 | 11 | 0.180 |
Why?
|
| Telencephalon | 1 | 2002 | 11 | 0.180 |
Why?
|
| Spinal Cord Injuries | 2 | 2022 | 277 | 0.180 |
Why?
|
| Pulmonary Embolism | 2 | 2017 | 188 | 0.180 |
Why?
|
| Neurologic Examination | 2 | 2014 | 186 | 0.180 |
Why?
|
| tau Proteins | 3 | 2025 | 250 | 0.180 |
Why?
|
| Diffusion Tensor Imaging | 5 | 2025 | 256 | 0.180 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 2096 | 0.180 |
Why?
|
| Epilepsy, Post-Traumatic | 1 | 2021 | 13 | 0.180 |
Why?
|
| Patient Acuity | 1 | 2021 | 66 | 0.180 |
Why?
|
| Consciousness Disorders | 1 | 2021 | 26 | 0.180 |
Why?
|
| DNA Damage | 2 | 2004 | 519 | 0.180 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 450 | 0.170 |
Why?
|
| Anesthesia | 1 | 2024 | 209 | 0.170 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2021 | 5 | 0.170 |
Why?
|
| Information Dissemination | 1 | 2023 | 193 | 0.170 |
Why?
|
| Withholding Treatment | 2 | 2021 | 76 | 0.170 |
Why?
|
| Interleukin-6 | 2 | 2016 | 414 | 0.170 |
Why?
|
| Inflammation | 3 | 2025 | 1489 | 0.160 |
Why?
|
| Cholesterol | 1 | 2023 | 540 | 0.160 |
Why?
|
| Single-Blind Method | 1 | 2021 | 241 | 0.160 |
Why?
|
| Cysteine Proteases | 1 | 2020 | 8 | 0.160 |
Why?
|
| Cathepsin B | 1 | 2020 | 8 | 0.160 |
Why?
|
| Astrocytes | 4 | 2022 | 280 | 0.160 |
Why?
|
| Oxidative Stress | 2 | 2004 | 798 | 0.160 |
Why?
|
| Algorithms | 4 | 2020 | 1677 | 0.160 |
Why?
|
| ROC Curve | 4 | 2016 | 611 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 3410 | 0.160 |
Why?
|
| Body Fluids | 1 | 2020 | 45 | 0.160 |
Why?
|
| Persistent Vegetative State | 2 | 2021 | 10 | 0.150 |
Why?
|
| Hydrocephalus | 2 | 2017 | 289 | 0.150 |
Why?
|
| Cognition | 2 | 2023 | 817 | 0.150 |
Why?
|
| Tissue and Organ Procurement | 1 | 2002 | 253 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 784 | 0.150 |
Why?
|
| Calcium | 1 | 2003 | 1033 | 0.140 |
Why?
|
| Probability | 1 | 2019 | 306 | 0.140 |
Why?
|
| Proteolysis | 2 | 2021 | 193 | 0.140 |
Why?
|
| Caspase 3 | 3 | 2014 | 127 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 274 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2018 | 89 | 0.140 |
Why?
|
| Spatial Memory | 1 | 2017 | 28 | 0.130 |
Why?
|
| Patient Admission | 1 | 2019 | 184 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 235 | 0.130 |
Why?
|
| Quality of Life | 3 | 2023 | 2086 | 0.130 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2017 | 44 | 0.130 |
Why?
|
| Spectrin | 2 | 2009 | 70 | 0.130 |
Why?
|
| Likelihood Functions | 1 | 2017 | 117 | 0.130 |
Why?
|
| Life Support Care | 1 | 2017 | 51 | 0.130 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 19 | 0.130 |
Why?
|
| Cross-Sectional Studies | 4 | 2025 | 3817 | 0.130 |
Why?
|
| Motor Activity | 3 | 2017 | 499 | 0.130 |
Why?
|
| Hypernatremia | 1 | 2017 | 32 | 0.130 |
Why?
|
| Microglia | 2 | 2017 | 139 | 0.130 |
Why?
|
| rho-Associated Kinases | 1 | 2017 | 48 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2015 | 1131 | 0.130 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 418 | 0.130 |
Why?
|
| Aftercare | 1 | 2018 | 153 | 0.130 |
Why?
|
| Morbidity | 1 | 2017 | 261 | 0.130 |
Why?
|
| Maze Learning | 2 | 2017 | 97 | 0.130 |
Why?
|
| Central Venous Catheters | 1 | 2017 | 51 | 0.120 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2017 | 98 | 0.120 |
Why?
|
| Hypoxia, Brain | 1 | 2016 | 34 | 0.120 |
Why?
|
| Encephalitis | 1 | 2017 | 120 | 0.120 |
Why?
|
| Unconsciousness | 1 | 2016 | 27 | 0.120 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2012 | 214 | 0.120 |
Why?
|
| Blood Gas Analysis | 2 | 2008 | 88 | 0.120 |
Why?
|
| Laser-Doppler Flowmetry | 3 | 2010 | 63 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1387 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2017 | 203 | 0.120 |
Why?
|
| Nanoparticles | 1 | 2019 | 292 | 0.120 |
Why?
|
| Research Design | 2 | 2022 | 715 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2016 | 205 | 0.120 |
Why?
|
| Risk Factors | 6 | 2025 | 10991 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2020 | 600 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2020 | 1135 | 0.110 |
Why?
|
| Lateral Ventricles | 1 | 2015 | 15 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 1299 | 0.110 |
Why?
|
| United States | 8 | 2025 | 11814 | 0.110 |
Why?
|
| Immunoassay | 1 | 2014 | 125 | 0.110 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2014 | 64 | 0.110 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2014 | 2 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2014 | 321 | 0.100 |
Why?
|
| Acute Disease | 3 | 2020 | 1151 | 0.100 |
Why?
|
| Thromboembolism | 1 | 2014 | 92 | 0.100 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2014 | 96 | 0.100 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 83 | 0.100 |
Why?
|
| Case-Control Studies | 6 | 2020 | 3417 | 0.100 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 395 | 0.100 |
Why?
|
| Cultural Diversity | 1 | 2014 | 78 | 0.100 |
Why?
|
| Models, Biological | 3 | 2017 | 1391 | 0.100 |
Why?
|
| Membrane Potentials | 2 | 2005 | 296 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2017 | 559 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2020 | 899 | 0.100 |
Why?
|
| Wounds, Gunshot | 1 | 2014 | 145 | 0.100 |
Why?
|
| Hospital Mortality | 2 | 2015 | 1073 | 0.100 |
Why?
|
| Intracranial Hypotension | 1 | 2012 | 10 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 240 | 0.090 |
Why?
|
| I-kappa B Proteins | 1 | 2012 | 37 | 0.090 |
Why?
|
| Nanotubes, Carbon | 1 | 2012 | 15 | 0.090 |
Why?
|
| Incidence | 2 | 2021 | 3349 | 0.090 |
Why?
|
| Partial Pressure | 1 | 2012 | 27 | 0.090 |
Why?
|
| Vascular Resistance | 2 | 2003 | 182 | 0.090 |
Why?
|
| Infusions, Intravenous | 2 | 2004 | 548 | 0.090 |
Why?
|
| Superoxide Dismutase | 2 | 2023 | 178 | 0.090 |
Why?
|
| Affect | 1 | 2013 | 167 | 0.090 |
Why?
|
| Fractures, Bone | 1 | 2014 | 211 | 0.090 |
Why?
|
| Minority Groups | 1 | 2014 | 257 | 0.090 |
Why?
|
| Axons | 1 | 2015 | 388 | 0.090 |
Why?
|
| Mice, Knockout | 4 | 2017 | 3828 | 0.090 |
Why?
|
| Sagittal Sinus Thrombosis | 1 | 2011 | 3 | 0.090 |
Why?
|
| Superior Sagittal Sinus | 1 | 2011 | 4 | 0.090 |
Why?
|
| Brain Diseases | 1 | 2014 | 302 | 0.090 |
Why?
|
| Informed Consent | 1 | 2014 | 344 | 0.090 |
Why?
|
| Ethanol | 1 | 2012 | 163 | 0.090 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2011 | 116 | 0.080 |
Why?
|
| Random Allocation | 2 | 2019 | 422 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2014 | 438 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 2935 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 790 | 0.080 |
Why?
|
| Skull Fractures | 1 | 2011 | 48 | 0.080 |
Why?
|
| Neurophysins | 1 | 2010 | 3 | 0.080 |
Why?
|
| Anxiety | 1 | 2017 | 1008 | 0.080 |
Why?
|
| Vasopressins | 1 | 2010 | 42 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 397 | 0.080 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2010 | 36 | 0.080 |
Why?
|
| Brain Edema | 1 | 2010 | 65 | 0.080 |
Why?
|
| Patient Selection | 1 | 2014 | 721 | 0.080 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 346 | 0.080 |
Why?
|
| Genotype | 2 | 2017 | 2609 | 0.080 |
Why?
|
| Protein Precursors | 1 | 2010 | 141 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 2337 | 0.080 |
Why?
|
| Survival Rate | 4 | 2017 | 2144 | 0.080 |
Why?
|
| Hypotension | 2 | 2019 | 184 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 1088 | 0.070 |
Why?
|
| Extracellular Fluid | 1 | 2008 | 11 | 0.070 |
Why?
|
| Peptides | 2 | 2022 | 709 | 0.070 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 156 | 0.070 |
Why?
|
| Models, Animal | 2 | 2017 | 456 | 0.070 |
Why?
|
| Nerve Degeneration | 1 | 2009 | 134 | 0.070 |
Why?
|
| Intracranial Hemorrhages | 2 | 2021 | 79 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 5 | 2015 | 4689 | 0.070 |
Why?
|
| Regional Blood Flow | 2 | 2010 | 195 | 0.070 |
Why?
|
| Cause of Death | 1 | 2010 | 510 | 0.070 |
Why?
|
| Hematoma, Subdural | 1 | 2007 | 28 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2010 | 406 | 0.060 |
Why?
|
| Observation | 1 | 2007 | 39 | 0.060 |
Why?
|
| Texas | 1 | 2015 | 3631 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2021 | 3711 | 0.060 |
Why?
|
| Stroke | 1 | 2014 | 1049 | 0.060 |
Why?
|
| Age Factors | 4 | 2017 | 2844 | 0.060 |
Why?
|
| Peptide Hydrolases | 2 | 2022 | 131 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 1841 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1948 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2024 | 1567 | 0.060 |
Why?
|
| Cell Survival | 2 | 2010 | 839 | 0.060 |
Why?
|
| Cerebral Ventricles | 1 | 2006 | 83 | 0.060 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2025 | 13 | 0.060 |
Why?
|
| Comparative Effectiveness Research | 1 | 2025 | 72 | 0.060 |
Why?
|
| Muscle Relaxation | 1 | 2005 | 11 | 0.060 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2005 | 13 | 0.060 |
Why?
|
| Electric Conductivity | 1 | 2005 | 80 | 0.060 |
Why?
|
| Cerebral Hemorrhage, Traumatic | 1 | 2004 | 3 | 0.060 |
Why?
|
| Feedback, Physiological | 1 | 2005 | 67 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2007 | 271 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2017 | 3111 | 0.060 |
Why?
|
| Dendrites | 2 | 2017 | 182 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2026 | 265 | 0.050 |
Why?
|
| Diffuse Axonal Injury | 1 | 2024 | 10 | 0.050 |
Why?
|
| Pyruvic Acid | 1 | 2004 | 35 | 0.050 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 55 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2004 | 90 | 0.050 |
Why?
|
| Multimodal Imaging | 1 | 2025 | 112 | 0.050 |
Why?
|
| Potassium Channels | 1 | 2005 | 156 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2011 | 1558 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 151 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2025 | 351 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2902 | 0.050 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 142 | 0.050 |
Why?
|
| Dalteparin | 1 | 2003 | 5 | 0.050 |
Why?
|
| Viscosity | 1 | 2003 | 39 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2025 | 189 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2004 | 147 | 0.050 |
Why?
|
| Charcoal | 1 | 2023 | 8 | 0.050 |
Why?
|
| Decision Making | 1 | 2009 | 688 | 0.050 |
Why?
|
| Elasticity | 1 | 2003 | 94 | 0.050 |
Why?
|
| Enoxaparin | 1 | 2003 | 43 | 0.050 |
Why?
|
| Nitrates | 1 | 2003 | 30 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 978 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2004 | 209 | 0.050 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 2003 | 10 | 0.050 |
Why?
|
| Nitrites | 1 | 2003 | 48 | 0.050 |
Why?
|
| Dominance, Cerebral | 1 | 2003 | 50 | 0.050 |
Why?
|
| Catalase | 1 | 2003 | 64 | 0.050 |
Why?
|
| Consent Forms | 1 | 2002 | 22 | 0.050 |
Why?
|
| Interinstitutional Relations | 1 | 2002 | 20 | 0.050 |
Why?
|
| Stress, Mechanical | 1 | 2003 | 177 | 0.050 |
Why?
|
| Caspase 6 | 1 | 2022 | 4 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2022 | 10 | 0.050 |
Why?
|
| Hypoxia | 1 | 2004 | 244 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2018 | 28 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 946 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 809 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2023 | 123 | 0.050 |
Why?
|
| Neurogranin | 1 | 2021 | 1 | 0.050 |
Why?
|
| Myelin Basic Protein | 1 | 2021 | 67 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 199 | 0.040 |
Why?
|
| Disease Progression | 2 | 2020 | 2201 | 0.040 |
Why?
|
| Child | 4 | 2014 | 26182 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2025 | 398 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 169 | 0.040 |
Why?
|
| Brain Death | 1 | 2002 | 74 | 0.040 |
Why?
|
| Neurosurgery | 1 | 2002 | 72 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2007 | 1017 | 0.040 |
Why?
|
| Vimentin | 1 | 2021 | 60 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 241 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2024 | 2557 | 0.040 |
Why?
|
| Sepsis | 1 | 2005 | 496 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2022 | 179 | 0.040 |
Why?
|
| RNA | 1 | 2024 | 515 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2017 | 1512 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2020 | 4659 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2021 | 315 | 0.040 |
Why?
|
| Amygdala | 1 | 2020 | 81 | 0.040 |
Why?
|
| Glucose | 1 | 2004 | 848 | 0.040 |
Why?
|
| Public Health | 1 | 2022 | 275 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 153 | 0.040 |
Why?
|
| Inpatients | 1 | 2023 | 541 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 288 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1616 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 380 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2020 | 586 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 266 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2002 | 558 | 0.040 |
Why?
|
| Thy-1 Antigens | 1 | 2018 | 18 | 0.040 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2002 | 338 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 555 | 0.040 |
Why?
|
| Pamphlets | 1 | 2018 | 22 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2002 | 545 | 0.030 |
Why?
|
| Gliosis | 1 | 2017 | 30 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2017 | 40 | 0.030 |
Why?
|
| Prosencephalon | 1 | 2017 | 41 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2017 | 34 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2025 | 893 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 240 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2002 | 974 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2017 | 101 | 0.030 |
Why?
|
| Military Medicine | 1 | 2017 | 52 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2017 | 113 | 0.030 |
Why?
|
| Patient Care | 1 | 2017 | 98 | 0.030 |
Why?
|
| Hypertension | 1 | 2025 | 1356 | 0.030 |
Why?
|
| Resuscitation | 1 | 2019 | 280 | 0.030 |
Why?
|
| Tissue Preservation | 1 | 2015 | 15 | 0.030 |
Why?
|
| South America | 1 | 2015 | 44 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 297 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1232 | 0.030 |
Why?
|
| Device Removal | 1 | 2017 | 224 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 4022 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 2015 | 47 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2015 | 191 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2002 | 1919 | 0.030 |
Why?
|
| Infant | 1 | 2010 | 13302 | 0.030 |
Why?
|
| Adie Syndrome | 1 | 2014 | 3 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 297 | 0.030 |
Why?
|
| Benchmarking | 1 | 2015 | 136 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2020 | 558 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2017 | 766 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 226 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 291 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2010 | 14994 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 235 | 0.030 |
Why?
|
| Ankyrins | 1 | 2015 | 96 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1592 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1594 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 1477 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 229 | 0.030 |
Why?
|
| Hematinics | 1 | 2014 | 60 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 2543 | 0.030 |
Why?
|
| Oximetry | 1 | 2014 | 177 | 0.030 |
Why?
|
| Veterans | 1 | 2025 | 1790 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2015 | 494 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 2569 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2014 | 113 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 1598 | 0.020 |
Why?
|
| Action Potentials | 1 | 2015 | 466 | 0.020 |
Why?
|
| Prevalence | 1 | 2019 | 2682 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2011 | 72 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 642 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2014 | 387 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2012 | 150 | 0.020 |
Why?
|
| Motorcycles | 1 | 2011 | 9 | 0.020 |
Why?
|
| Protein Stability | 1 | 2011 | 166 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 599 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2011 | 397 | 0.020 |
Why?
|
| Rabbits | 1 | 2011 | 572 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 1230 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2011 | 105 | 0.020 |
Why?
|
| Cell Count | 1 | 2010 | 213 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2014 | 791 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2012 | 448 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2014 | 379 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 641 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2010 | 135 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2014 | 861 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2011 | 274 | 0.020 |
Why?
|
| Health Personnel | 1 | 2014 | 547 | 0.020 |
Why?
|
| Pupil | 1 | 2009 | 45 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2014 | 983 | 0.020 |
Why?
|
| Neurochemistry | 1 | 2008 | 5 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 430 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 1338 | 0.010 |
Why?
|
| Silicones | 1 | 2005 | 30 | 0.010 |
Why?
|
| Minocycline | 1 | 2005 | 43 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2009 | 687 | 0.010 |
Why?
|
| Rifampin | 1 | 2005 | 122 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2011 | 864 | 0.010 |
Why?
|
| Pia Mater | 1 | 2003 | 9 | 0.010 |
Why?
|
| Prealbumin | 1 | 2003 | 27 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 80 | 0.010 |
Why?
|
| Arterioles | 1 | 2003 | 38 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2003 | 121 | 0.010 |
Why?
|
| Cobra Cardiotoxin Proteins | 1 | 2002 | 5 | 0.010 |
Why?
|
| Capillaries | 1 | 2003 | 65 | 0.010 |
Why?
|
| Nerve Growth Factor | 1 | 2002 | 21 | 0.010 |
Why?
|
| Hormones | 1 | 2003 | 163 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2002 | 54 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 229 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2002 | 314 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2003 | 245 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 650 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2002 | 264 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2003 | 345 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 824 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 1218 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2003 | 468 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 453 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 1007 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2003 | 498 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2002 | 590 | 0.010 |
Why?
|
| Mitochondria | 1 | 2003 | 761 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2002 | 998 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2002 | 1264 | 0.010 |
Why?
|